News

For the primary end point, the 3 dose options atogepant (AbbVie) were associated with a reduction ranging from 3.9 to 4.2 days in the mean number of headache days per month for those with episodic migraine.

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed employing the MoCA-T app as a means of cognitive screening in rural and ethnically diverse populations.

Coauthor and member of the American Academy of Sleep Medicine board of directors, Lynn Marie Trotti, MD, MSc, discussed key takeaways from the new guideline, which encompasses the first updates since 2007.

Lesions in the canalicular and intracranial optic nerve, area postrema, medulla, and cervical spinal cord were prominent in patients with aquaporin-4–NMOSD.

The innovative nonsurgical device has previously received market authorization to treat gait deficit due to mild-to-moderate symptoms from multiple sclerosis.

The full approval for BNT162b2 (Comirnaty; Pfizer/BioNTech) will afford physicians greater prescribing capability and is expected to play a role in driving workplace vaccine mandates.

The potential of a new investigational treatment for C9orf72-associated amyotrophic lateral sclerosis and frontotemporal could offer long-lasting effects for patients.

This NeurologyLive® Peers & Perspectives series features experts in the diagnosis and treatment of Alzheimer disease discussing the recent approval of aducanumab, its implications for Alzheimer disease, and other promising therapies and diagnostic technologies in development.

The director of the Cerebrovascular Center at Cleveland Clinic discussed areas within hospital care that need addressing to improve outcomes of patients with stroke.

Here's what is coming soon to NeurologyLive.

The director of the Center for Brain Health at Miami University Miller School of Medicine discussed how much influence people have on lowering their Alzheimer disease risk.

Michael Weiner, MD, professor of radiology and biomedical imaging, medicine, psychiatry, and neurology at the University of California–San Francisco, discussed the findings of a systematic review aimed at evaluating models that predict dichotomous Aß.

Tardive dyskinesia can present many challenges in its treatment and can be difficult to differentiate from similar disorders.

The new guideline addresses recent FDA-approved prescription medications to treat narcolepsy, idiopathic hypersomnia, and Kleine-Levin syndrome.

Experts provide a summary of the management of commonly encountered risk factors for secondary ischemic stroke and transient ischemic attack based on the newly published 2021 AHA/ASA recommendations.

Neurology News Network for the week ending August 21, 2021.

The agent’s safety profile has been studied in more than 1200 individuals to date across several inflammatory diseases, with data indicating that the high selectivity of fenebrutinib may limit off-target effects.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 20, 2021.

The chief medical officer of Wave Life Sciences spoke on the FOCUS-C9 study and the potential of WVE-004 to generate positive outcomes for patients.

Trigger avoidance-only strategies don’t actually help migraine patients improve. These are the proactive behaviors that do.

The professor of neurology at the Mayo Clinic College of Medicine highlighted the importance of the diagnostic process and implementing an early treatment regimen for patients with NMOSD.

Yanhong Shi, PhD, director, stem cell biology research, City of Hope National Medical Center, discussed the potential of a new brain organoid model, which was developed to study sporadic Alzheimer disease.

Investigators used statistical analysis to evaluate the effectiveness of the treatment method, with results indicating it could be a viable method for patients with MS.

Investigators found that phase advance was associated with late-stage PD, mostly due to active offset advance, amplitude reduction, and weakened robustness.

The potential of a new investigational treatment, WVE-004, was discussed by the chief medical officer of Wave Life Sciences, the company that developed the molecule for C9-ALS and C9-FTD.

After the FDA approval for Jazz Pharmaceuticals' oxybates combination therapy, Robert Iannone, MD, MSCE, offered insight into the potential effects the drug may have on the clinical care of patients with idiopathic hypersomnia.

The global head of Neurodegeneration at Roche/Genentech shared insight into the development of the company’s NeuroToolKit and its use in its Alzheimer disease research.

γ-Hydroxybutyrate, known as GHB or oxybate, is a physiological compound present in the human body as both a precursor and degradation product of GABA.

Patients with focal seizures showed a median 25.2% reduction in the frequency of focal seizures, the most common seizure type in patients with tuberous sclerosis complex.

Recent advances in stereoelectroencephalography and laser ablation may help convert those who may be candidates for pediatric epilepsy surgery to those who proceed with a consultation.